OncoMatch

OncoMatch/Clinical Trials/NCT04966663

Using ctDNA to Determine Therapies for Lung Cancer

Is NCT04966663 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for non small cell lung cancer.

Phase 2RecruitingUniversity Health Network, TorontoNCT04966663Data as of May 2026

Treatment: Nivolumab · Pemetrexed · Gemcitabine · Cisplatin · CarboplatinThis is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Small Cell Lung Cancer

Disease stage

Required: Stage T1-2N0M0

Complete surgical resection of T1-2N0M0 NSCLC or T3/T4 multifocal NSCLC

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

No prior chemotherapy or radiotherapy is allowed for the current diagnosis of resected NSCLC.

Cannot have received: radiation therapy

No prior chemotherapy or radiotherapy is allowed for the current diagnosis of resected NSCLC.

Cannot have received: immune-mediated anti-cancer therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1, nivolumab, agents targeting CD73, agents targeting CD39, agents targeting adenosine receptors)

Prior receipt of any immune-mediated anti-cancer therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies including nivolumab and agents targeting CD73, CD39, or adenosine receptors

Cannot have received: conventional or investigational anticancer therapy

Receipt of any conventional or investigational anticancer therapy within 21 days or radiotherapy within 14 days prior to the scheduled first dose of study treatment

Lab requirements

Blood counts

Adequate organ and marrow function as defined in Table 4 (3.1.1)

Kidney function

Adequate organ and marrow function as defined in Table 4 (3.1.1)

Liver function

Adequate organ and marrow function as defined in Table 4 (3.1.1)

Adequate organ and marrow function as defined in Table 4 (3.1.1)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify